The portfolio company CMA Microdialysis restructures operations

Bure Equity’s portfolio company CMA Microdialysis sells its preclinical business and its subsidiary Dilab. CMA Microdialysis continuing operations will be renamed to Dipolyn Medical AB.

 
 
For more information see enclosed press releases and Dipylon Medicals web page:
www.dipylonmedical.com
 

For more information contact:
Patrik Tigerschiöld, CEO
Tel. +46 8 614 00 20

wkr0001.pdf

wkr0002.pdf

wkr0003.pdf